Bitterman Kevin 4

What Happened

• Kevin Bitterman, a director of Disc Medicine, was granted a derivative award covering 6,212 shares on 2026-06-18. The grant is reported at $0.00 per share (total reported value $0) and is recorded as an award/other acquisition (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-18; Report filed: 2026-06-23.
• Transaction type/code: Award/Grant (A); 6,212 shares @ $0.00 (derivative).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Vesting: The underlying shares vest upon the earlier of (i) the Company's 2027 annual meeting or (ii) the one-year anniversary of the grant date, subject to continued service (footnote F1).
• Ownership/beneficial interest: Proceeds from any sale of shares issued on exercise will be transferred to Atlas Venture Life Science Advisors, LLC; Bitterman disclaims ownership for Section 16 purposes except for any pecuniary interest (footnote F2).

Context

• This filing reports a time/service-based equity award (derivative). It does not indicate any immediate sale or cashless exercise of shares. For retail investors, awards to directors are common for compensation and retention; they differ from purchases in signaling direct personal capital deployment.